Agilon Health (AGL) Is Up 0.79% in One Week: What You Should Know
Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AGL - Agilon Health, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$53.20
DETAILS
HIGH:
$81.00
LOW:
$16.00
MEDIAN:
$49.00
CONSENSUS:
$53.20
DOWNSIDE:
55.39%
Stock News
Why Fast-paced Mover Agilon (AGL) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
agilon health: Q1 Inflection And A New CEO Set Up A Multi-Year Rerating
agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational.
Is the Options Market Predicting a Spike in agilon health Stock?
Investors need to pay close attention to AGL stock based on the movements in the options market lately.
agilon health to Participate in Upcoming Conferences
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that members of its management team will participate in investor meetings and industry discussions at the following conferences: Truist Securities Healthcare Disruptors & Digital Health Conference on Tuesday, June 23, 2026 in New York. Management will participate in an ACO Model panel discussion at 1:50pm ET and conduct o.
These ETFs Owned Russell 2000's Biggest Winners Before They Soared 400%+ In 2026
Investors searching for the biggest stock winners of 2026 may be surprised to learn they already own some of them through small-cap ETFs.
Are You Looking for a Top Momentum Pick? Why Agilon Health (AGL) is a Great Choice
Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Agilon Health (AGL) This Year?
Here is how Agilon Health (AGL) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.
Despite Fast-paced Momentum, Agilon (AGL) Is Still a Bargain Stock
Agilon (AGL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
Here is how Agilon Health (AGL) and Amarin (AMRN) have performed compared to their sector so far this year.
Agilon (AGL) Is Attractively Priced Despite Fast-paced Momentum
Agilon (AGL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.
Shares of Agilon Health cratered in 2025, driven by financial underperformance and a guidance suspension.
Agilon Health Operational Initiatives Begin Showing Results
Agilon Health Inc. (NYSE:AGL) shares are soaring on Thursday as the company recently announced an increase in its full-year 2026 guidance. The company operates and manages a network of independent physicians.
agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
Agilon Health (AGL) Q1 Earnings and Revenues Top Estimates
Agilon Health (AGL) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to break-even earnings per share a year ago.
Agilon (AGL) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Agilon (AGL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
agilon health Reports First Quarter 2026 Results
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the first quarter ended March 31, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities. We.
Australia's AGL Energy lifts lower end of fiscal 2026 earnings outlook
Australia's AGL Energy on Wednesday raised the lower end of its full-year profit forecast, helped by the continued strong operational and financial performance of its business since its last update in February.
agilon health Appoints Tim O'Rourke as Chief Executive Officer
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL) (the “Company”), the trusted partner empowering physicians to transform health care in our communities, today announced the appointment of Tim O'Rourke as Chief Executive Officer and a member of the Company's Board of Directors, effective May 7. He succeeds Ronald A. Williams, who has served as Executive Chairman since August 2025 and will continue as Chairman of the Board. The appointment comes as agilon enters a new phase following.
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Price Targets
Agilon Health upgraded to Equal Weight from Underweight at Barclays
$81.00
(was $88.07)
Andrew Mok
·
Barclays
Agilon Health price target raised to $72 from $37.50 at Wells Fargo
$72.00
(was $60.66)
Wells Fargo
Agilon Health upgraded to Buy from Hold at Jefferies
$48.00
(was $27.85)
Jack Slevin
·
Jefferies
Agilon Health upgraded to Buy from Hold at Deutsche Bank
$49.00
(was $27.85)
Deutsche Bank
Agilon Health price target adjusted to $33 from $2 at Deutsche Bank
$33.00
(was $19.84)
George Hill
·
Deutsche Bank
Agilon Health price target adjusted to $16 at Evercore ISI after reverse split
$16.00
(was $18.47)
Evercore ISI
Agilon Health price target lowered to $1.50 from $5 at Wells Fargo
$1.50
(was $28.00)
Wells Fargo
Agilon Health price target lowered to $1.10 from $2.40 at Jefferies
$1.10
(was $27.38)
Jack Slevin
·
Jefferies
Citi Downgrades agilon health Inc (AGL) to Sell
$2.50
(was $63.00)
Daniel Grosslight
·
Citigroup
Agilon Health downgraded to Underperform from Buy at BofA
$3.00
(was $88.38)
Adam Ron
·
Bank of America Securities
agilon health Inc (AGL) PT Lowered to $4 at Deutsche Bank
$4.00
(was $140.00)
George Hill
·
Deutsche Bank
Agilon Health initiated with a Neutral at Baird
$6.00
(was $144.00)
Michael Ha
·
Robert W. Baird
agilon health Inc (AGL) PT Raised to $6.50 at Truist Securities
$6.50
(was $141.25)
Jailendra Singh
·
Truist Financial
Agilon Health (AGL) Stock: $33 Target And Buy Rating
$33.00
(was $628.25)
David MacDonald
·
Truist Financial